Cancer genetics and the cardiotoxicity of the therapeutics.
about
Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer TherapyCardiac effects of anticancer therapy in the elderlyCardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next LevelStrain imaging to detect cancer therapeutics-related cardiac dysfunction: are we there yet?Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cardiac complications of chemotherapy: role of imaging.A comprehensive protein-protein interactome for yeast PAS kinase 1 reveals direct inhibition of respiration through the phosphorylation of Cbf1.Zebrafish: A marvel of high-throughput biology for 21(st) century toxicology.PAS kinase is activated by direct SNF1-dependent phosphorylation and mediates inhibition of TORC1 through the phosphorylation and activation of Pbp1Heme oxygenase-1 regulates mitochondrial quality control in the heart.Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively.Emerging paradigms in cardiomyopathies associated with cancer therapies.How to monitor cardiac toxicity of chemotherapy: time is muscle!Heart failure-specific changes in protein kinase signalling.The Notch pathway: a novel target for myocardial remodelling therapy?Cancer chemotherapy and cardiac arrhythmias: a review.Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.Deconvoluting Kinase Inhibitor Induced Cardiotoxicity.Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.Arrhythmic complications of tyrosine kinase inhibitors.Cardiotoxicity from the cardiologist's perspective.Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology.Protecting the heart in cancer therapyMyocardial Reprogramming Medicine: The Development, Application, and Challenge of Induced Pluripotent Stem Cells
P2860
Q26797138-11B0D389-DF7C-4563-B880-A262C4A45BEFQ26863244-61A3C07F-BD89-4C7D-A511-081A0B32A2D7Q26864094-1B6C42D8-01EA-4CB1-8CDB-AF97AD7202E5Q30385954-4F906D06-964F-4CE3-AB47-FD386D05A6C5Q30401812-DAD8BC1A-B87E-4EE0-A8FF-4228B1161286Q30415201-72A04CA1-0070-46EA-AA4A-0ECDAAF189A7Q33881412-6238BACE-4984-4752-AE2F-4EA3EB82EB1EQ34462608-9D1B254E-8716-42B2-80BE-49009127905EQ35027599-7A52A351-840E-488A-A691-F2C7B1BEA6B8Q36819774-8C9BA800-B305-4674-A476-7C775C6BDFF2Q38097736-EFD3C7AD-1616-4E0D-83FA-5816BCE5E55BQ38132645-2E18A263-61F1-4B41-B75F-40E7BD7704EDQ38171887-E55EE2D2-A4F1-4DCD-A63B-987F47CD54A0Q38186583-4B8E66A0-FF6F-4AA9-BF91-0A9BAE579585Q38223705-BA83CD94-D1C3-4F00-9335-47720F70E8B0Q38313870-3650FD57-DBE0-41A5-B35A-47FC8C79AC8EQ38508938-8AE1156C-EF46-4338-B028-A686DC4C510FQ38814429-212C0E57-731C-4CB4-AEC3-D06B4B749992Q38938410-B7A98CD5-8B74-48AA-8FA4-24407268A50AQ38956949-D034219E-DACA-44A3-A53A-8E40F2C7909AQ38978097-63A5BA93-DF74-44EF-B74F-F18869596594Q38978582-1A5C19DA-8BE9-4E06-B9CB-1B6A291EB920Q42703704-B81A3A2A-99E2-4F35-9E71-2690B834932EQ49315568-A58AAEBD-57DF-4065-83A1-34F3EFD7F90FQ53661913-3BF5D347-7F7F-42D6-AA3B-CC9C8DB679A7Q57821006-7AD29C4D-5170-46C1-B808-1F2C2CB218F5Q59072379-2D9C3FE4-5D6A-4C98-959A-65DCA856854D
P2860
Cancer genetics and the cardiotoxicity of the therapeutics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cancer genetics and the cardiotoxicity of the therapeutics.
@en
type
label
Cancer genetics and the cardiotoxicity of the therapeutics.
@en
prefLabel
Cancer genetics and the cardiotoxicity of the therapeutics.
@en
P50
P1476
Cancer genetics and the cardiotoxicity of the therapeutics
@en
P2093
Kyle L Kolaja
P304
P356
10.1016/J.JACC.2012.05.066
P407
P577
2013-01-01T00:00:00Z